Peritransplant Treg-Based Immunomodulation to Improve VCA Outcomes
Technical Report,30 Sep 2016,29 Sep 2018
Childrens Hospital of Philadelphia Philadelphia United States
Pagination or Media Count:
We have undertaken studies of how Treg cells, or pharmacologic modulators of Treg function called HDAC inhibitors, may be used to enhance outcomes in VCA recipients, using murine models of orthotopic limb transplantation. Using this model, we have shown that expansion of Tregs can be used to significantly prolong orthotopic limb allograft survival. In addition, we have shown that Treg infusion or use of an HDAC inhibitor can be used to promote long-term orthotopic VCA survival.
- Medicine and Medical Research